US 12,378,241 B2
Pyridine derivative as FGFR and VEGFR dual inhibitors
Zhengxia Chen, Shanghai (CN); Meibi Dai, Shanghai (CN); Yang Zhang, Shanghai (CN); and Shuhui Chen, Shanghai (CN)
Assigned to CGeneTech (Suzhou,China) CO., Ltd., Jiangsu (CN)
Appl. No. 17/629,566
Filed by CGeneTech (Suzhou,China) CO., Ltd., Jiangsu (CN)
PCT Filed Jul. 24, 2020, PCT No. PCT/CN2020/104550
§ 371(c)(1), (2) Date Jan. 24, 2022,
PCT Pub. No. WO2021/018047, PCT Pub. Date Feb. 4, 2021.
Claims priority of application No. 201910684252.3 (CN), filed on Jul. 26, 2019; application No. 201911266249.6 (CN), filed on Dec. 11, 2019; and application No. 202010230493.3 (CN), filed on Mar. 27, 2020.
Prior Publication US 2022/0267324 A1, Aug. 25, 2022
Int. Cl. C07D 471/04 (2006.01); A61P 35/00 (2006.01)
CPC C07D 471/04 (2013.01) [A61P 35/00 (2018.01)] 20 Claims
 
1. A compound represented by formula (I) or a pharmaceutically acceptable salt thereof,

OG Complex Work Unit Chemistry
wherein,
R1 is selected from H and C1-3 alkyl optionally substituted by 1, 2 or 3 Ra;
R2 and R3 are each independently selected from H, F, Cl, Br, I, OH, NH2 and CH3;
R4 is selected from H, C1-6 alkyl, C1-3 alkoxy, C3-5 cycloalkyl, tetrahydropyranyl and 1,3-dioxolanyl, wherein, the C1-6 alkyl, C1-3 alkoxy, C3-5 cycloalkyl, tetrahydropyranyl and 1,3-dioxolanyl are optionally substituted by 1, 2 or 3 Rb;
L is selected from —N(R5)C(═O)—, —N(R5)S(═O)2—, —N(R5)C(═O)N(R5)—, —N(R5)CH2— and —N(R5)—;
R5 is each independently selected from H and C1-3 alkyl;
ring B is selected from pyrazolyl and imidazolyl, the pyrazolyl and imidazolyl are optionally substituted by 1 or 2 R6;
R6 is selected from H and C1-3 alkyl;
Ra and Rb are each independently selected from H, F, Cl, Br, I, OH, NH2, CN and CH3.